drugset
drugset / Trial / NCT05739877

Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

NCT05739877 ↗

Phase 1 Unknown 34 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01(2.5/500 mg x1 tablets) at fed state

Timeline

Start
2023-03-17
Primary completion
2023-04-07
Completion
2023-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-1229_01 Unknown 2.5 mg —
Subject DA-1229_01 Unknown 500 mg —

Indications

No indication recorded.